Les has said this many times dating back at least to January, 2015. The word "planning" is artful in that there are no timelines and anyway "plans" change. He has said a number of times that a PR about legal action would be forthcoming as part of a string of PRs calculated to raise the share price in the midst of complaints about toxic financing. What happened? Change of "plans"?
These responses are carefully worded and scrubbed by legal counsel if not written by them. There is no accountability whatsoever. Much of what Les says is useless and a waste of everybody's time. Essentially, management is hiding behind counsel as it has been wrt the SAB.
They will not say anything beyond their responses to IkeEsq. and there will be little if any clarification. The responses presage a short and uneventful ASM. The direction is now very clear. Silence will continue essentially upon the advice of counsel as management does not want to prejudice in any way the regulatory process. It does not want to be accused of "cherry picking." Well then, why did they reveal the number of patients alive as of 3/17? Why did they release an article in the JTM? Could that prejudice the regulatory process? Why were only snippets of the updated data revealed at SNO? Isn't that the same as "cherry picking"?
Why are they pioneering various regulatory paths? Is it because the primary and secondary endpoints are a mixed bag, not undeniable and perhaps not SS? The clear implication is that they are not anything to write home about and not favourable enough for regulatory approvals at least insofar as the FDA is concerned. Otherwise, if they were, the usual regulatory paths would be open. The excuses of pseudo-progression and cross-over confounding the trial results now cause a shift in emphasis to a new "primary" criteria, to which of course the FDA has not given the green light, and that is the "long tail", the new gold standard for immunological approaches such as DC VAX L. Didn't LL hint at this a long time ago? Patients are living longer and a way needs to be found to approve such a therapy?
Accordingly, it appears almost certain that everything is riding on the long tail and the primary/secondary end points are argued as antiquated and not appropriate for Immunological approaches. This is the new regulatory pathway that NWBO is pioneering. And hoping that the data supporting the long tail is persuasive enough to be deemed undeniable and over riding other criteria. Hence, they need a touch down pass in the fourth quarter and fourth down. A field goal will fall short(pun intended).
If this interpretation is correct, then it is obvious that NWBO has nothing more to say. And it will not bring anything else into play at least until after top line is announced. Forget about legal proceedings, other trials including combos with DC VAX L, possible BOs, partnerships, etc. Without grand slam results wrt the long tail, nothing else matters. There is no concern for the share price now. If results are less than stellar, we all go home. If they turn out to be stellar, the share price will appreciate from a very low base, but the days of $50, $30, $15 are all but a memory. We will be lucky if we achieve even a couple of bucks. Any more will take years even with competent management. LP and friends have enough shares that even a couple of bucks in share price will be a great haul. Retail shareholders? Not so much. Sorry to repeat the mantra but "stay tuned". Very disappointing.
Market Data 
Markets 
AI
